GlobeNewswire

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data [...]
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
05/11/2026
Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast [...]
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
05/11/2026
– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net [...]
Medicus Pharma to Present at BIO-Europe 2026
05/11/2026
Medicus Chief Medical Officer will Highlight Company’s Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs PHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma [...]
Cronos Group Reports 2026 Third Quarter Results
05/11/2026
Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q3 20 26 increased by 73% year-over-year on an organic, constant-currency basis Generated record net [...]
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
05/11/2026
- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 - - Additional one-year clinical data from [...]
Resalis Therapeutics Announces First-in-Human Data for RES-010 Demonstrating Safety and Tolerability with Early Weight Loss Signals
05/11/2026
The completed Phase 1a study data in healthy volunteers showed early signs of pharmacodynamic activity supporting further clinical evaluation of RES-010 The Phase 1b study in healthy overweight and moderately obese [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026 , Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
CurePSP Names First Recipients of Biomarker Accelerator Program, Awarding Its Largest Research Grants to Date
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CurePSP has awarded more than $1.4 million through its Biomarker Accelerator Program to three researchers working to find reliable biomarkers for progressive supranuclear [...]
Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease
05/11/2026
Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up [...]
ArrayPatch boucle un tour de financement d’amorçage sursouscrit de 3,2 millions d’euros pour faire progresser ses traitements par micro-aiguilles de nouvelle génération
05/11/2026
CORK, Irlande, 05 nov. 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (« ArrayPatch »), une société de biotechnologie développant des traitements novateurs à base de micro-aiguilles, a annoncé aujourd’hui la clôture réussie de [...]
ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics
05/11/2026
CORK, Ireland, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, today announced the successful completion of the second close of [...]
Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms
05/11/2026
Series A financing co-led by Sofinnova Partners and RA Capital alongside founding investor Oxford Science Enterprises with support from Cancer Research Horizons and the University of Oxford, bringing together a world- [...]
Ethris Reports Positive Topline Phase 2a Data for Nasal mRNA Candidate ETH47 in Asthma Patients Challenged with Rhinovirus
05/11/2026
40-fold lower virus load compared to placebo on Day 2, at the peak of viral replication Exposure-response relationship observed, with greater interferon lambda (IFNλ) exposure associated with greater antiviral and [...]
9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
05/11/2026
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7 [...]
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
05/11/2026
$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M- [...]
Interim report 9M 2026
05/11/2026
Strong Q3 sales leading to 9M at 7% organic sales growth and adj. EBITDA margin of 37.9%. 2026 outlook confirmed: 7-8% organic sales growth and adj. EBITDA margin at the higher end of the 37-38% range. Ester Baiget, [...]
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
05/11/2026
Egetis Therapeutics’ lead asset, EMCITATE ® , is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 [...]
Siemens Healthineers to Rebrand In Vitro Diagnostics Business as Olyrian Diagnostics
05/11/2026
Siemens Healthineers announced today it has initiated the carve-out process for its in vitro diagnostics business Tarrytown, New York, USA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The company is preparing its Diagnostics [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum